Abstract
The overall pharmaceutical market is changing. A more personalised medicine approach is replacing the concept of blockbuster drugs and the “one size fits all” model. The two main forces that fuel the growth of nano-enabled drug technologies are the low aqueous solubility of new chemical entities and the pharmaceutical market itself, as the development of novel drug delivery systems can extend the drug patent lifetime. Classical solubilisation techniques, such as salt formation and the use of cyclodextrins can only be applied to drugs with ionisable groups or specific molecular weight ranges in order to fit in the cavity of the cyclodextrin. However, drug nanonisation, or particle size reduction into the nanosize range, is a versatile technique that can be applied to a wide range of pharmaceutical compounds. Nano-drugs exhibit higher surface area per unit of volume, which leads to faster dissolution kinetics and hence potentially improved bioavailability. Marketed nano-drugs are mostly crystalline due to the improved physical stability afforded by the crystalline state whereas amorphous nano-drugs have been largely neglected in spite of generating higher saturation solubility compared to their crystalline counterparts. Due to the vast potential in the global pharmaceutical market, many technologies have been licensed to produce nano-drugs. Among them, the most successful by far is Nanocrystal® Technology based on wet milling methods. In this review, the main methods to generate and characterise nano-drugs are covered and also, the biopharmaceutical characteristics of the marketed nano-drugs are discussed.
Keywords: Amorphous, Bioavailability, Crystalline, Nanomaterials, Nanoparticles, Stability, Nanocrystal, Nanoamorphous.
Current Topics in Medicinal Chemistry
Title:Emerging Nanonisation Technologies: Tailoring Crystalline Versus Amorphous Nanomaterials
Volume: 15 Issue: 22
Author(s): Dolores R. Serrano, Kieran H. Gallagher and Anne Marie Healy
Affiliation:
Keywords: Amorphous, Bioavailability, Crystalline, Nanomaterials, Nanoparticles, Stability, Nanocrystal, Nanoamorphous.
Abstract: The overall pharmaceutical market is changing. A more personalised medicine approach is replacing the concept of blockbuster drugs and the “one size fits all” model. The two main forces that fuel the growth of nano-enabled drug technologies are the low aqueous solubility of new chemical entities and the pharmaceutical market itself, as the development of novel drug delivery systems can extend the drug patent lifetime. Classical solubilisation techniques, such as salt formation and the use of cyclodextrins can only be applied to drugs with ionisable groups or specific molecular weight ranges in order to fit in the cavity of the cyclodextrin. However, drug nanonisation, or particle size reduction into the nanosize range, is a versatile technique that can be applied to a wide range of pharmaceutical compounds. Nano-drugs exhibit higher surface area per unit of volume, which leads to faster dissolution kinetics and hence potentially improved bioavailability. Marketed nano-drugs are mostly crystalline due to the improved physical stability afforded by the crystalline state whereas amorphous nano-drugs have been largely neglected in spite of generating higher saturation solubility compared to their crystalline counterparts. Due to the vast potential in the global pharmaceutical market, many technologies have been licensed to produce nano-drugs. Among them, the most successful by far is Nanocrystal® Technology based on wet milling methods. In this review, the main methods to generate and characterise nano-drugs are covered and also, the biopharmaceutical characteristics of the marketed nano-drugs are discussed.
Export Options
About this article
Cite this article as:
Serrano R. Dolores, Gallagher H. Kieran and Healy Marie Anne, Emerging Nanonisation Technologies: Tailoring Crystalline Versus Amorphous Nanomaterials, Current Topics in Medicinal Chemistry 2015; 15 (22) . https://dx.doi.org/10.2174/1568026615666150605122917
DOI https://dx.doi.org/10.2174/1568026615666150605122917 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
TRIM65 in White Matter Lesions, Innate Immunity, and Tumor
Current Molecular Pharmacology Biosimilars: Current Scientific and Regulatory Considerations
Current Clinical Pharmacology Genetic Heterogeneity of Hepatitis Viruses and its Clinical Significance
Current Drug Targets - Inflammation & Allergy Pleiotropic Effects of Cathepsin D
Endocrine, Metabolic & Immune Disorders - Drug Targets A Review on Pharmacokinetics Properties of Antiretroviral Drugs to Treat HIV-1 Infections
Current Computer-Aided Drug Design Curcumin, Hesperidin, and Rutin Selectively Interfere with Apoptosis Signaling and Attenuate Streptozotocin-Induced Oxidative Stress- Mediated Hyperglycemia
Current Neurovascular Research Autologous CD19-Targeted Chimeric Antigen Receptor (CAR)T-Cells as the Future of Systemic Lupus Erythematosus Treatment
Current Rheumatology Reviews Antioxidant Food Supplements and Obesity-Related Inflammation
Current Medicinal Chemistry Pharmacological Implications of MMP-9 Inhibition by ACE Inhibitors
Current Medicinal Chemistry Serum Interleukin-33 is a Predictor of Depression in Patients with Acute Ischemic Stroke
Current Neurovascular Research Supersaturation as a Tool For Skin Penetration Enhancement
Current Pharmaceutical Design Inflammatory Cyclooxygenase Activity and PGE<sub>2</sub> Signaling in Models of Alzheimer’s Disease
Current Immunology Reviews (Discontinued) Targeting the Nuclear Transport Machinery by Rational Drug Design
Current Pharmaceutical Design Dual Receptor-Specific Peptides Modified Liposomes as VEGF siRNA Vector for Tumor-Targeting Therapy
Current Gene Therapy Targeting Transcription Factors for Cancer Therapy
Current Pharmaceutical Design Repositioning of DHFR Inhibitors
Current Topics in Medicinal Chemistry Prediction of Cytochrome 450 Mediated Drug-Drug Interactions by Three-Dimensional Cultured Hepatocytes
Mini-Reviews in Medicinal Chemistry Kawasaki Disease and Its Treatment – An Update
Current Rheumatology Reviews Risk Factors for Cardiovascular Disease in Psoriasis: Relation to Inflammation Assessed by the Severity and Duration of Illness
Inflammation & Allergy - Drug Targets (Discontinued) The Combination of New Immunotherapy and Radiotherapy: A N ew Potential Treatment for Locally Advanced Non-Small Cell Lung Cancer
Current Clinical Pharmacology